The information on this web site is being disclosed for the purposes of AIM Rule 26 and was last updated on 20 February 2019.
The main country of operation and country of incorporation is the UK. Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody® and Moditope® platforms. The Company's mission is to develop therapeutic cancer vaccines that stimulate the patient's immune system to mount an active response to 'reject' or kill the growing tumour.
After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.
Fri, 21 Jun 2019 08:21:00
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00